. 2014 Apr 17;16(3):609–619. doi: 10.1208/s12248-014-9600-0

Table I.

Model Parameter Estimates Describing LDH and NSE Dynamics

	Parameter (units)	Estimate	95% CI	BSV %	95% CI
Mutual	λ (U weeks⁻¹)	0.0067	0.0004–0.018	213	96.1–292
	ɣ (weeks⁻¹)	0.377	0.294–0.512	15	NE
	KDE (weeks⁻¹)	1.16	NE	54.8	NE
	α (U⁻¹ weeks⁻¹)	1.32	0.905–1.78	47.5	9.87–73.4
	β (weeks⁻¹)	0.831	0.652–0.987	NE	NE
	Correlation (ηLDH_0, ηNSE₀)	0.684	0.457–0.782	NA	NA
LDH	MRT_LDH (weeks)	0.311	0.249–0.519	15	NE
	K _{in_LDH} (IU L⁻¹ weeks⁻¹)^a	553	NA	NA	NA
	K _{in_LDH} if GCSF coadministration (IU L⁻¹ weeks⁻¹)^a	757	NA	NA	NA
	K _{D_LDH} (IU L⁻¹ weeks⁻¹)^a	671	NA	NA	NA
	LDH₀ (IU L⁻¹)	352	301–412	61.5	47.3–74.6
	Residual error	0.205	0.182–0.229	NA	NA
NSE	MRT_NSE (weeks)	0.301	0.236–0.363	15	NE
	K _{in_NSE} (ng mL⁻¹ weeks⁻¹)^a	15.0	NA	NA	NA
	K _{D_NSE} (ng mL⁻¹ weeks⁻¹)^a	126	NA	NA	NA
	NSE₀ (ng mL⁻¹)	47.7	35.4–62.7	92.1	64.6–120
	Residual error	0.402	0.306–0.506	NA	NA

Abbreviations: λ linear rate of disease progression, ɣ resistance parameter, KDE first-order elimination constant of chemotherapy exposure (KDE and its associated interpatient variability were fixed according to the longest real half-life time of the combination drugs administered to patients [23]), α chemotherapy efficacy parameter, β radiotherapy efficacy parameter, MRT mean residence time (MRT = 1/K _OUT), LDH ₀ LDH values at time = 0, K _{in_LDH} basal (physiological) LDH synthesis, K _{D_LDH} LDH synthesis driven by disease, K _{in_NSE} basal NSE synthesis, K _{D_NSE} NSE synthesis driven by disease, NSE ₀ NSE values at time = 0, BSV between-subjects variability expressed in CV%, Residual error constant on logarithmic scale. NE not estimated, NA not applicable

^aSecondary parameters